MACIVIVAProject reference: 646122
Funded under :
H2020-EU.126.96.36.199. - Developing next generation nanomaterials, nanodevices and nanosystems
MAnufacturing process for Cold-chain Independent VIrosome-based VAccines
Total cost:EUR 8 438 905,63
EU contribution:EUR 5 338 886,88
Call for proposal:H2020-NMP-PILOTS-2014See other projects for this call
Funding scheme:RIA - Research and Innovation action
MACIVIVA is a highly interdisciplinary consortium among well established and innovative SMEs with scientific excellence and complementary industrial world-leading experts with unique expertise and know-how in virosome technology, spray and freeze drying, large scale manufacturing and packaging. MACIVIVA will pave the path to other large scale thermostable nanopharmaceuticals products for therapeutic and prophylactic vaccines and other potential applications for direct application by non-invasive routes.
Liquid products are inherently prone to physical and/or chemical modifications and degradations. Solid vaccine dosage formats (e.g. powder) may prevent molecular motion and shear-induced degradation, and slow down degradation involving water and oxygen radicals, resulting in improved stability and enhanced shelf-life of vaccines. The cold chain storage is still fundamental for preserving the bioactivity of most liquid and freeze-dried vaccines, and a reconstitution step prior to administration is required for freeze dried vaccines that are usually administered intramuscularly or subcutaneously. These reconstituted freeze dried vaccines harbor important instability and must be used within hours and kept refrigerated. Because most liquid and reconstituted freeze-dried vaccines are susceptible to degradations, it may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection.
For addressing liquid virosome-based vaccine instability and improving their shelf-life outside the cold chain, MACIVIVA will explore new galenic vaccine formulations through careful screening of excipients, stabilization and drying methods for generating new vaccine solid forms that can be easily self-administered. Robust “universal” manufacturing processes for upscale production of virosome dried powder for the non-invasive intranasal, oral and sublingual routes should be achieved by month 42.
EU contribution: EUR 1 755 073,75
J H OORTWEG 21
2333 CH LEIDEN
EU contribution: EUR 0
ROUTE DE LA CORNICHE 4
EU contribution: EUR 0
EU contribution: EUR 1 697 777,5
CAMBRIDGE ROAD 15
NG2 5NA NOTTINGHAN
EU contribution: EUR 1 061 723,13
FRANKLAND ROAD BLAGROVE
SN5 8YG SWINDON
EU contribution: EUR 824 312,5